Fredrik Bäckhed has recently received EUR 150,000 from ERC in order to develop an idea from the group’s ERC project towards commercial application. The concept that they are going to develop concerns treating bacteria in the gut with drugs to prevent them from producing molecules that impair insulin signaling. In the long run, research could lead to a treatment for insulin resistance and type 2 diabetes.
“It is very exciting and stimulating to be involved in developing potential drugs, though I am fully aware that this is very difficult and risky,” Fredrik coments.